Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Droxypropine is a small molecule drug of the phenylpiperidine class that acts as a cough suppressant (antitussive)[4][3][5]. It is classified under the ATC code R05DB17 and is used in the treatment of cough and cold symptoms[2][4]. Droxypropine works by suppressing or inhibiting the cough reflex, likely through central nervous system mechanisms similar to other antitussives in its class[5]. The drug has reached up to Phase II clinical trials for investigational indications but does not appear to be widely marketed or approved in major regions[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on droxypropine.